Illumina Offers FDA-Approved NGS Cancer Companion Test Kit
Zacks Investment Research | Jul 02, 2017 10:56PM ET
Global leader in the field of DNA sequencing and array-based technologies, Illumina, Inc. (NASDAQ:ILMN) recently announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines. This new kit fulfills the most up-to-date guidance for RAS testing to determine eligibility of epidermal growth factor receptor (EGFR) inhibitors in metastatic colorectal cancer. This product also offers extended gene coverage that implies the simultaneous detection of 56 RAS mutations contraindicated for anti-EGFR therapy. This product also helps in Integrated Workflow by providing comprehensive diagnostic solution which includes library prep, sequencing and clinical report.
This Extended RAS Panel kit is intended to be used on the Illumina MiSeqDx System to detect patients who are eligible for metastatic colorectal cancer treatment with Vectibix. Notably, Vectibix represents an innovative treatment option for first-line treatment for patients with wild-type RAS metastatic colorectal cancer (mCRC).
Per management, the Extended RAS Panel paves the way for broader-based genomics solutions as a first companion diagnostic and Pre-Market Application (PMA) approval in Oncology. The shipment of this kit will start in the third quarter of 2017.
According to Markets and Markets, the global next-generation sequencing market is estimated to reach a worth of $12.45 billion by 2022, at a CAGR of 20.5%.
For the majority of the past one year, Illumina has been trading above the Zacks categorized Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.